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Abstract:
Guillain-Barre Syndrome is a rare post-infection inflammatory disorder. It is caused by
the cross-reactivity of antibodies produced from a recent infection which then attack the
gangliosides of the peripheral nervous system. Guillain-Barre syndrome includes multiple
subtypes which are categorized based on both disease course and symptoms, which include
length of progression phase, pain, and cranial nerve involvement. This paper will serve as a
review of diagnostic tools and treatment options used for Guillain-Barre syndrome patients. It
will also discuss recent research on these topics as well as studies on viral outbreaks which may
be linked to Guillain-Barre syndrome. These will include Zika, a large viral outbreak from 2016,
and COVID-19, a current pandemic at the time of completion of this paper. Lastly, an overview
of potential future studies will be explored on these topics.

One sentence summary: This review explores the current diagnostic tools and treatments used
for Guillain-Barre Syndrome as well as discusses ongoing research regarding the disorder.
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Introduction:
Guillain-Barre Syndrome (GBS) is an inflammatory disorder in which the peripheral
nervous system experiences damage by an inappropriate immune response. This disorder is
associated with a recent viral or bacterial infection within six weeks of the onset of symptoms
(See Figure 1). The most common infection that leads to GBS is by Campylobacter jejuni, which
typically presents with diarrhea, fever, and occasionally vomiting. Other infections known to be
associated with the disorder are Epstein-Barr virus and cytomegalovirus. Studies have
determined that after the initial infection antibodies produced against the pathogen are able to
cross react with gangliosides in the peripheral nervous system which may be molecularly similar.
Once the immune system has begun to attack these nerves the onset of symptoms begins.(1)
Symptoms of GBS include weakness in extremities, numbness, and ascending paralysis. Severe
cases of GBS can be life-threatening as the antiganglioside antibodies can attack the respiratory
system. This disorder most commonly affects males above the age of sixty, however cases in
women and children have also been reported. What causes an individual to be more susceptible
to developing GBS is still unknown.
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Figure 1.

Adapted from van Doorn, et al. (6) Physical representation of the progression of GBS beginning
with an initial infection. After infection the antiganglioside antibodies attack the peripheral
nervous system which then starts the course of GBS. As antibody levels decrease the patient will
experience an improvement in symptoms.
Diagnosis of GBS:
GBS is a rare disorder that can be difficult to accurately diagnose. Weakness of the limbs
and areflexia, the most common symptoms experienced in GBS, are often attributed to other
diseases due to the infrequent diagnosis of GBS. This along with a wide range of diversity in
other symptoms can be problematic when identifying the cause of a patient’s symptoms. In
children, GBS is even more difficult to recognize, resulting in only one-third receiving a correct
diagnosis at admission.(1) Currently, only two diagnostic tools are used to diagnose GBS:
electromyography and cerebrospinal fluid analysis.
Electromyography is a diagnostic tool which uses probes, either attached to the skin or
inserted into the muscle, that send out electrical impulses to detect nerve activity in potential
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GBS cases. In GBS patients the electrical impulses being sent may show signs of slowed nerve
conduction or conduction being blocked completely. These findings indicate that the patient’s
paralysis can be contributed to nerve damage in the limbs.
GBS has several subtypes based on how the peripheral nerves are being affected by the
autoantibodies. Electromyography is a useful tool to assist in identifying which subtype a patient
may be experiencing. These subtypes are acute inflammatory demyelinating neuropathy (AIDP),
acute motor axonal neuropathy (AMAN), and acute motor and sensory axonal neuropathy
(AMSAN).(2) AIDP is the most common subtype of GBS and is characterized by the
demyelination of peripheral nerves. AMAN does not show signs of demyelination but has a
clinical presentation of decreased compound muscle action potential, specifically affecting the
motor neurons.(3) While AMAN only affects the motor neurons, AMSAN includes damage to
both the motor and sensory neurons. Determining which subtype a patient has can help to obtain
a more accurate prognosis. Even with electromyography there is a possibility that one subtype
may mimic another. This can occur with reversible conduction failure (RCF), an
electrophysiological characteristic that can be seen in patients with AMAN subtype. If the patient
is not tested multiple times using electromyography they can be miscategorized under the AIDP
subtype.(2) Under current diagnostic protocol, when determining if a patient is suffering from
GBS, this test is typically only performed once.
Cerebrospinal fluid analysis is the second tool that medical professionals use to diagnose
GBS. When a patient is suspected of developing GBS a cerebrospinal fluid sample is obtained
through a lumbar puncture. This fluid is then analyzed for any abnormalities. Typically with
GBS patients there will be a significant increase in protein levels in the cerebrospinal fluid while
maintaining a normal white blood cell count. However, this factor does not lead to a definitive
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diagnosis. Many other conditions that affect the peripheral nervous system, such as chronic
inflammatory demyelinating polyneuropathy (CIDP), will have a similar result when using this
analysis. CIDP also presents similarly to GBS in the early stages of the disorder and current
diagnostic tools cannot differentiate between the two at disease onset.(4)
Currently, electromyography and cerebrospinal fluid analysis are the only diagnostic
tools used for potential GBS cases. However, neither provides a definite diagnosis. Given this
analysis of current diagnostic tools used for GBS, it is imperative that new tools for identifying
GBS cases and determining the specific subtype are developed. This will ensure a quick and
accurate diagnosis and prognosis for patients.

Treatment:
Treatment options for GBS are dependent on the severity of the disease. Currently, in
mild cases there is typically no prescribed treatment. A mild case is defined as an individual who
is still able to walk with or without assistance. In these cases, however, physical therapy may be
beneficial. For more severe cases there are two treatment options, plasma exchange and
intravenous immunoglobulin.
Plasma exchange is a procedure in which the patient’s blood is removed from their body
and filtered before being returned to the body system. The goal of this treatment is to remove the
harmful, soluble antibodies that are causing damage to the nerves from the blood.(5) However,
the timing of this treatment plays a key role in determining how effective it is. A study conducted
in North America showed that plasma exchange had the greatest improvement when given
within two weeks of the onset of symptoms. It was also found to be effective to a lesser degree at
four weeks.(6) Only individuals who could not walk without assistance were given the treatment
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in this study. Based on their findings it may be beneficial to repeat this experiment with
individuals who have varying severity of the disease to determine if this timing applies to all
cases of GBS.
Intravenous immunoglobulin is another treatment for GBS and is more commonly used
than plasma exchange. For this treatment, donated blood is processed and separated such that the
immunoglobulin is isolated. The antibodies, which are in the immunoglobulin, are then given to
the patient through an IV to help stop the harmful, cross reacting antibodies from damaging the
nerves. Several mechanisms have been suggested as to how this treatment is beneficial. These
mechanisms include a blockage of receptors found on macrophages which prevents the harmful
antibodies from attacking the myelin and that the donor antibodies help to regulate the
antiganglioside antibodies or cytokines. Although this treatment is more common it has not been
shown to be more effective than plasma exchange.(7) Previous studies have also shown that a
combination of the two treatments does not have a significant effect on improving recovery
time.(8)
While these treatments can be beneficial to a patient with GBS they have both been found
to be time-sensitive. Given the difficulty in diagnosing GBS, it is likely that a significant portion
of affected patients will miss the two-week window for either treatment to be the most effective.
On top of this, 5-10% of individuals who initially improve from either treatment will begin to
experience deterioration again.(1) It is still unclear as to why this may occur. However, it is clear
that more studies should be done to determine other beneficial treatments for GBS that are not
restricted by time.
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Current Research:
Given the limitations on current diagnostic tools it is imperative that research be
conducted on discovering more definitive ways of diagnosing GBS. Recent studies have focused
on the presence of biomarkers in an attempt to differentiate between GBS and other similar
autoimmune diseases. Some studies on the effectiveness of alternate treatment options have been
conducted as well, the findings from these will be discussed in detail.
With the current rise in viral outbreaks, such as Zika and SARS-CoV-2, in recent years
studies have been conducted that look at the percentage of these cases that contract GBS to
determine a possible link between GBS and these viruses. This information can help to
determine what types of viruses or infections are most likely to result in GBS and thus the
hospitals can be better prepared to manage patients with this diagnosis.

IL-8 as a biomarker:
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common
chronic autoimmune neuropathy. Unlike GBS, there has not been any autoantibodies or antigen
identified as a trigger for the disorder currently. However, the two disorders do share some
similarities. CIDP also presents with weakness in the arms and legs which is caused by damage
to the myelin sheath that surrounds the peripheral nerves.(10) It is also recommended that
treatment should be started as soon as possible to prevent the loss of nerve axons. A significant
difference between these two diseases is that CIDP is chronic whereas GBS is a monophasic
disorder. Other differences are evident between GBS and CIDP when it comes to disease course,
prognosis, and responsiveness to steroids. Similar to GBS, CIDP can be treated with intravenous
immunoglobulin and plasma exchange, however steroids are also typically prescribed as well. In
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contrast, research has shown that corticosteroids may worsen GBS in some cases.(11) This
difference in treatment effectiveness makes a prompt and accurate diagnosis crucial.
A recent study has provided evidence of another possible diagnostic tool that could be
used to differentiate between CIDP and GBS. The article published in November of 2019 found
that IL-8 levels in the cerebrospinal fluid were significantly elevated in patients diagnosed with
GBS. IL-8 is a cytokine which is responsible for activating neutrophils in inflammatory areas.
(12) In this study the authors compared groups of individuals who had been diagnosed with
GBS, CIDP, non-inflammatory polyneuropathies, migraines, and a group with functional
neurological disorders. The authors included individuals with several different types of
non-inflammatory polyneuropathy which included drug-related, cryptogenic, and hereditary
origins. All patients were from the Neurology Clinic of the University Hospitals of Geneva
between the years 2010 and 2018.(4,13)
For this study, cerebrospinal fluid was acquired from each individual and concentrations
of IL-8, IL-6, and TNF⍺ were analyzed. Specifically, the authors were most interested in IL-8
due to it being a pro-inflammatory chemokine. Its expression is stimulated by specific cytokines,
such as IL-1, IL-6, and IL-12.(4) To determine the significance of differences in the compared
groups the mean and standard deviation were calculated and ANOVA was performed. The level
of significance was set to p<0.05. (4,13)
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Figure 2.

Breville, G., Lascano, A.M., Roux-Lombard, P. et al.Eur Cytokine Netw 30, 130–134 (2019).
Second, the authors performed another experiment in which they analyzed levels of
proteins, IgG index, albumin quotient, and IgG intrathecal synthesis if present in the
cerebrospinal fluid.(4) They also observed the C-reactive protein levels in the serum, which can
be used as an indicator for inflammation. Individuals who were diagnosed with CIDP had protein
levels that ranged from 0.4-0.6mg/ml whereas GBS protein levels were found to range from
0.6-1.1mg/ml. For reference, normal protein levels of cerebrospinal fluid are typically
0.15-0.6mg/ml. All other measurements taken during this experiment were deemed not
significant for this study. However, one individual diagnosed with GBS was found to have a
white blood cell count of 29 per cubic millimeter. The normal range is 0-5 WBC per cubic
millimeter.
The main findings from this paper is that there is potential for IL-8 to be a biomarker for
diagnosing GBS as it appears that it can be used to differentiate between similar neurological
11

diseases, such as CIDP.(13) The authors hypothesize that if this diagnostic tool is used, IL-8
concentrations should be analyzed in the cerebrospinal fluid as it will be more reliable than if it
is measured in blood. They suggest that there may be fluctuations in concentrations changing
throughout the day due to the circadian rhythm.(9) While this study appears promising, future
research involving larger groups of patients are required as this initial study was limited to only
four patients with GBS.(4) Additionally, these future studies will help to establish a standardized
cutoff for IL-8 concentrations in the cerebrospinal fluid. In doing so this will further assist in
differentiating between GBS and other diseases.
This pilot study serves as a starting point for further research regarding the use of IL-8 as
a biomarker for GBS. While this experiment is valuable to expanding the field of diagnostic tools
currently involved in neurological diseases, the sample size of each group was small. Because of
this there is a possibility of skewing the results in a way that may not accurately reflect the data.
In future studies involving IL-8 a larger group should be used to confirm the results found in this
study. The authors also state that when looking at IL-8 concentrations they arbitrarily chose 60
pg/ml as the cutoff for their experiments (See Figure 2). While the mean concentration of IL-8
for GBS patients was significantly higher than the other groups, this random selection of the
cutoff does not have much significance. Their choice may skew the results in this study.(13)
Possible next steps for research on this topic could be to include a larger patient
population, as stated previously. Doing so could either provide more evidence to back up the
findings of this study or refute the collected data. Another possible avenue could be to implement
other proinflammatory cytokine analysis into potential future studies, which could bring to light
another possible biomarker for GBS. Lastly, future research should include testing the
concentration of these cytokines in blood samples to determine if the authors were correct in
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their suggestion that cerebrospinal fluid is more reliable. If incorrect this could suggest a less
invasive diagnostic tool for medical professionals to implement into practice. (13)

Methylprednisolone:
Methylprednisolone is a corticosteroid that is known to have anti-inflammatory
properties. It accomplishes this by binding to specific nuclear receptors which then affects gene
expression and inhibits the production of proinflammatory cytokines. (14) Early studies
regarding its use have suggested that corticosteroids may also be beneficial in treating pain. (15)
It is because of these properties that the drug has been of interest in regards to its effects on
recovery from GBS.
One study involving the drug was performed as a double-blind, placebo-controlled,
randomized study, in which they had 233 participants who had been diagnosed with GBS. Each
was assigned to receive either intravenous methylprednisolone or a placebo for five days with
concurrent intravenous immunoglobulin treatment. (16) A disability score was taken at the
beginning of treatment and analyzed for improvement in each participant four weeks after
randomization. It was found that 68% of the methylprednisolone group and 56% of the placebo
improved by one grade or more on the disability score. Given this information it was concluded
that there was no significant difference in improvement between the two groups. However, the
authors did note that further studies should be conducted on the drug in terms of treatment for
GBS.
Another study that was published in 2016 compiled data from six previous trials
regarding the use of methylprednisolone in cases of GBS. The studies were either randomized
controlled trials (RCT) or quasi-RCT and included both adults and children. From the data
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collected they compared disability grade changes after four weeks similar to the previous study
discussed. (11) The scale was graded from zero to six with increasing disability; grade zero was
individuals that were deemed healthy while grade six was deceased. From the six trials 297
participants in total received corticosteroids while 290 were placed in the placebo group. From
this research the authors found that four trials using an oral form of corticosteroids saw less
improvement in the steroid group versus the placebo group. The other two trials involving
intravenous methylprednisolone showed no significant difference between the groups. (11)
Given the data collected from these two studies it does not seem beneficial to include
methylprednisolone or other corticosteroids as a treatment plan option for GBS patients. In the
case of oral steroids they seem to have a negative effect and could potentially delay recovery
further. (11) While the data does not show significant improvement in either use, it is still not
well understood why this is. Future research is required to fully understand how the
corticosteroid is not able to assist in decreasing inflammation and improving symptoms in cases
of GBS.

Zika Virus:
There are many infectious pathogens that have been linked to an increased risk of
developing GBS. However, prior to a study published in 2016 Zika virus had not been associated
with the disorder. From October 2013 to April 2014 a large Zika outbreak occurred in French
Polynesia. During this outbreak over 32,000 individuals were suspected of having been infected
with Zika virus. (17) Of this group 42 patients developed GBS after infection (See Figure 3). The
goal of this study was to determine if there was an association between Zika and GBS. The
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authors were also interested in examining if dengue virus co-infection or immunity played a role
in susceptibility to GBS.
Dengue virus is a common arbovirus with forty percent of the world’s population living
in areas at risk of dengue. (18) Symptoms of dengue infection include body aches, nausea, and
rash. (19) This virus had already been linked to causing GBS, however Zika had not. During the
2013 Zika outbreak there was a concurrent dengue outbreak that affected the region. (17) This
occurrence allowed for the authors to study not only Zika but also how dengue could affect GBS
case numbers.

Figure 3.

Graph comparing the number of cases of Zika virus versus the number of cases of GBS by week.
Cao-Lormeau, V.-M., Blake, A., et al. (2016). Guillain-Barré Syndrome outbreak associated with Zika virus
infection in French Polynesia: a case-control study. The Lancet, 387(10027), 1531–1539.
https://doi.org/10.1016/s0140-6736(16)00562-6
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For this study the authors formed three groups of patients from the Centre Hospitalier de
Polynésie Française (CHPF) in Papeete, Tahiti, French Polynesia. The first group was made up
of the 42 patients that had been diagnosed with GBS, while the other two groups were used as
control groups: group two was patients with non-febrile illnesses and group three was patients
who had been diagnosed with Zika but that had not developed any neurological disorders. Group
two was used to estimate the proportion of Zika virus infections in the general population while
group three was used to investigate the possible role of past dengue infection in developing GBS
in a Zika virus infected patient.
To accomplish their goals the authors took blood samples from all patients. For the GBS
group and group two IgM and IgG levels were determined for both Zika and dengue virus while
group three was only tested for IgG to Zika and dengue virus. The third group was not tested for
IgM antibodies. Given that IgM is produced as a first response to a new infection and this group
was already diagnosed with Zika, it was not deemed necessary. (17)
From these experiments it was found that 93% of GBS patients had IgM antibodies
against Zika, and of these 74% did not have IgM antibodies against dengue virus. It was also
found that there was not a significant increase in dengue virus incidence between the GBS group
and group two. Given this information it was concluded that dengue virus infection or immunity
did not play a role in GBS susceptibility. Based on a 66% attack rate, the percentage of an at-risk
population that contracts the disease during a specified time interval, GBS cases were estimated
to be 0.24 per 1,000 Zika infections. (17) These findings also supported that Zika virus should be
added to the list of infectious pathogens susceptible to causing GBS. Lastly, the authors suggest
that at risk countries should be prepared to have an adequate capacity of intensive care beds to
manage patients with Guillain-Barré syndrome.
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COVID-19:
SARS-CoV-2 is the virus responsible for coronavirus disease 19. At the completion of
this paper coronavirus disease 19 (COVID-19) is an ongoing global pandemic that is currently
responsible for 2.7 million deaths. (20) Neurological symptoms of the disease include loss of
taste and smell, tingling and numbness in the hands and feet, and muscle weakness. (21) In a
recent study it was found that neurological symptoms were seen in 36.4% of individuals with
COVID-19. (22) Currently, mRNA vaccines are being produced and almost 398 million have
been administered worldwide. (20) While this is a relatively new and rapidly evolving situation,
there are already published case studies regarding GBS and Covid-19.
An article published in September of 2020 outlined a case of GBS in a 36-year-old male
who was immunocompromised and COVID-19 positive. (23) In this case the patient was
admitted to the hospital 10 day after being diagnosed with COVID-19. During his six day stay he
was given oxygen via nasal cannula as well as several drugs which improved his overall state. At
discharge he did not have any neurological symptoms. (23) Four days after being discharged the
patient presents again to the emergency room, however this time he is experiencing numbness
and tingling in his extremities, as well as weakness in his legs that is causing difficulty walking.
Cerebrospinal fluid is taken for analysis. Clinical findings highly suggest that the patient
is experiencing GBS and treatment using intravenous immunoglobulin is started. However even
with treatment the patient’s state continued to decline which then led to intubation for 13 days.
Ultimately, the patient stayed in the hospital for 23 days and was then released to a physical
therapy facility in a stable condition.
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A second paper published around the same time served as a review for published cases of
GBS following infection by SARS-CoV-2. At the time of publication approximately 31 cases of
COVID-19 related GBS had been reported. Of these cases the youngest patient was age 5 while
the oldest was 84. (24) Currently, there is only one case study that has been published of a child
developing GBS after being infected with coronavirus. (25) In most of these cases GBS
presented typically one to four weeks post infection, however in two cases symptoms began at
the time of infection. (26) While it is too early to claim there is a definite link between GBS and
COVID-19 the authors concluded that it is a possibility. To determine if this association is
legitimate more data and further studies are necessary.
Suggestions for future studies regarding the association between GBS and COVID-19
include studying the relationship between COVID-19 and the nervous system as well as
comparing COVID-19 related GBS to non-COVID-19 GBS cases. (26,27) Additionally, while
there is currently no correlation between a specific variant of GBS and COVID-19 this may be
useful data to collect if another coronavirus outbreak occurs in the future. (28) Lastly, current
data shows that GBS symptoms begin approximately 10 days after infection by SARS-CoV-2
which is a similar interval seen with GBS in association to other infections. (29,30) As more data
is acquired with the spread of COVID-19, a timeline should be made showing the average onset
of GBS symptoms after infection.

Future research and conclusion:
GBS is a rare autoimmune disorder that is difficult to quickly diagnose and treat.
Currently used diagnostic tools are not definitive and treatment options are time-sensitive. While
recent studies have shown some promising insight on new ways to diagnose GBS there is still
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much more research required in this field. Moving forward it is paramount that future studies
focus on finding better ways to diagnose and treat this disorder.
On top of this, increases in viral outbreaks as seen in recent years may contribute to an
increase in annual cases worldwide. Currently, COVID-19 has caused a global pandemic which
may be associated with the development of GBS. As this global situation continues more studies
should be conducted to determine if SARS-CoV-2 should be added to the list of pathogens
known to cause GBS. Knowing which infections contribute to the development of GBS will
assist in better planning for patient care. As these outbreaks occur affected countries will need to
be prepared by increasing intensive care bed capacity as well as medical staff to care for these
patients. While there are still many questions surrounding this rare autoimmune disorder it is
imperative that further research be conducted in this field.
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